Cargando…

The association of smoking status with SARS‐CoV‐2 infection, hospitalization and mortality from COVID‐19: a living rapid evidence review with Bayesian meta‐analyses (version 7)

AIMS: To estimate the association of smoking status with rates of (i) infection, (ii) hospitalization, (iii) disease severity and (iv) mortality from SARS‐CoV‐2/COVID‐19 disease. DESIGN: Living rapid review of observational and experimental studies with random‐effects hierarchical Bayesian meta‐anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Simons, David, Shahab, Lion, Brown, Jamie, Perski, Olga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590402/
https://www.ncbi.nlm.nih.gov/pubmed/33007104
http://dx.doi.org/10.1111/add.15276
_version_ 1783600794799439872
author Simons, David
Shahab, Lion
Brown, Jamie
Perski, Olga
author_facet Simons, David
Shahab, Lion
Brown, Jamie
Perski, Olga
author_sort Simons, David
collection PubMed
description AIMS: To estimate the association of smoking status with rates of (i) infection, (ii) hospitalization, (iii) disease severity and (iv) mortality from SARS‐CoV‐2/COVID‐19 disease. DESIGN: Living rapid review of observational and experimental studies with random‐effects hierarchical Bayesian meta‐analyses. Published articles and pre‐prints were identified via MEDLINE and medRxiv. SETTING: Community or hospital, no restrictions on location. PARTICIPANTS: Adults who received a SARS‐CoV‐2 test or a COVID‐19 diagnosis. MEASUREMENTS: Outcomes were SARS‐CoV‐2 infection, hospitalization, disease severity and mortality stratified by smoking status. Study quality was assessed (i.e. ‘good’, ‘fair’ and ‘poor’). FINDINGS: Version 7 (searches up to 25 August 2020) included 233 studies with 32 ‘good’ and ‘fair’ quality studies included in meta‐analyses. Fifty‐seven studies (24.5%) reported current, former and never smoking status. Recorded smoking prevalence among people with COVID‐19 was generally lower than national prevalence. Current compared with never smokers were at reduced risk of SARS‐CoV‐2 infection [relative risk (RR) = 0.74, 95% credible interval (CrI) = 0.58–0.93, τ = 0.41]. Data for former smokers were inconclusive (RR = 1.05, 95% CrI = 0.95–1.17, τ = 0.17), but favoured there being no important association (21% probability of RR ≥ 1.1). Former compared with never smokers were at somewhat increased risk of hospitalization (RR = 1.20, CrI = 1.03–1.44, τ = 0.17), greater disease severity (RR = 1.52, CrI = 1.13–2.07, τ = 0.29) and mortality (RR = 1.39, 95% CrI = 1.09–1.87, τ = 0.27). Data for current smokers were inconclusive (RR = 1.06, CrI = 0.82–1.35, τ = 0.27; RR = 1.25, CrI = 0.85–1.93, τ = 0.34; RR = 1.22, 95% CrI = 0.78–1.94, τ = 0.49, respectively), but favoured there being no important associations with hospitalization and mortality (35% and 70% probability of RR ≥ 1.1, respectively) and a small but important association with disease severity (79% probability of RR ≥ 1.1). CONCLUSIONS: Compared with never smokers, current smokers appear to be at reduced risk of SARS‐CoV‐2 infection, while former smokers appear to be at increased risk of hospitalization, increased disease severity and mortality from COVID‐19. However, it is uncertain whether these associations are causal.
format Online
Article
Text
id pubmed-7590402
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-75904022020-10-27 The association of smoking status with SARS‐CoV‐2 infection, hospitalization and mortality from COVID‐19: a living rapid evidence review with Bayesian meta‐analyses (version 7) Simons, David Shahab, Lion Brown, Jamie Perski, Olga Addiction Reviews AIMS: To estimate the association of smoking status with rates of (i) infection, (ii) hospitalization, (iii) disease severity and (iv) mortality from SARS‐CoV‐2/COVID‐19 disease. DESIGN: Living rapid review of observational and experimental studies with random‐effects hierarchical Bayesian meta‐analyses. Published articles and pre‐prints were identified via MEDLINE and medRxiv. SETTING: Community or hospital, no restrictions on location. PARTICIPANTS: Adults who received a SARS‐CoV‐2 test or a COVID‐19 diagnosis. MEASUREMENTS: Outcomes were SARS‐CoV‐2 infection, hospitalization, disease severity and mortality stratified by smoking status. Study quality was assessed (i.e. ‘good’, ‘fair’ and ‘poor’). FINDINGS: Version 7 (searches up to 25 August 2020) included 233 studies with 32 ‘good’ and ‘fair’ quality studies included in meta‐analyses. Fifty‐seven studies (24.5%) reported current, former and never smoking status. Recorded smoking prevalence among people with COVID‐19 was generally lower than national prevalence. Current compared with never smokers were at reduced risk of SARS‐CoV‐2 infection [relative risk (RR) = 0.74, 95% credible interval (CrI) = 0.58–0.93, τ = 0.41]. Data for former smokers were inconclusive (RR = 1.05, 95% CrI = 0.95–1.17, τ = 0.17), but favoured there being no important association (21% probability of RR ≥ 1.1). Former compared with never smokers were at somewhat increased risk of hospitalization (RR = 1.20, CrI = 1.03–1.44, τ = 0.17), greater disease severity (RR = 1.52, CrI = 1.13–2.07, τ = 0.29) and mortality (RR = 1.39, 95% CrI = 1.09–1.87, τ = 0.27). Data for current smokers were inconclusive (RR = 1.06, CrI = 0.82–1.35, τ = 0.27; RR = 1.25, CrI = 0.85–1.93, τ = 0.34; RR = 1.22, 95% CrI = 0.78–1.94, τ = 0.49, respectively), but favoured there being no important associations with hospitalization and mortality (35% and 70% probability of RR ≥ 1.1, respectively) and a small but important association with disease severity (79% probability of RR ≥ 1.1). CONCLUSIONS: Compared with never smokers, current smokers appear to be at reduced risk of SARS‐CoV‐2 infection, while former smokers appear to be at increased risk of hospitalization, increased disease severity and mortality from COVID‐19. However, it is uncertain whether these associations are causal. John Wiley and Sons Inc. 2020-11-17 2021-06 /pmc/articles/PMC7590402/ /pubmed/33007104 http://dx.doi.org/10.1111/add.15276 Text en © 2020 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Simons, David
Shahab, Lion
Brown, Jamie
Perski, Olga
The association of smoking status with SARS‐CoV‐2 infection, hospitalization and mortality from COVID‐19: a living rapid evidence review with Bayesian meta‐analyses (version 7)
title The association of smoking status with SARS‐CoV‐2 infection, hospitalization and mortality from COVID‐19: a living rapid evidence review with Bayesian meta‐analyses (version 7)
title_full The association of smoking status with SARS‐CoV‐2 infection, hospitalization and mortality from COVID‐19: a living rapid evidence review with Bayesian meta‐analyses (version 7)
title_fullStr The association of smoking status with SARS‐CoV‐2 infection, hospitalization and mortality from COVID‐19: a living rapid evidence review with Bayesian meta‐analyses (version 7)
title_full_unstemmed The association of smoking status with SARS‐CoV‐2 infection, hospitalization and mortality from COVID‐19: a living rapid evidence review with Bayesian meta‐analyses (version 7)
title_short The association of smoking status with SARS‐CoV‐2 infection, hospitalization and mortality from COVID‐19: a living rapid evidence review with Bayesian meta‐analyses (version 7)
title_sort association of smoking status with sars‐cov‐2 infection, hospitalization and mortality from covid‐19: a living rapid evidence review with bayesian meta‐analyses (version 7)
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590402/
https://www.ncbi.nlm.nih.gov/pubmed/33007104
http://dx.doi.org/10.1111/add.15276
work_keys_str_mv AT simonsdavid theassociationofsmokingstatuswithsarscov2infectionhospitalizationandmortalityfromcovid19alivingrapidevidencereviewwithbayesianmetaanalysesversion7
AT shahablion theassociationofsmokingstatuswithsarscov2infectionhospitalizationandmortalityfromcovid19alivingrapidevidencereviewwithbayesianmetaanalysesversion7
AT brownjamie theassociationofsmokingstatuswithsarscov2infectionhospitalizationandmortalityfromcovid19alivingrapidevidencereviewwithbayesianmetaanalysesversion7
AT perskiolga theassociationofsmokingstatuswithsarscov2infectionhospitalizationandmortalityfromcovid19alivingrapidevidencereviewwithbayesianmetaanalysesversion7
AT simonsdavid associationofsmokingstatuswithsarscov2infectionhospitalizationandmortalityfromcovid19alivingrapidevidencereviewwithbayesianmetaanalysesversion7
AT shahablion associationofsmokingstatuswithsarscov2infectionhospitalizationandmortalityfromcovid19alivingrapidevidencereviewwithbayesianmetaanalysesversion7
AT brownjamie associationofsmokingstatuswithsarscov2infectionhospitalizationandmortalityfromcovid19alivingrapidevidencereviewwithbayesianmetaanalysesversion7
AT perskiolga associationofsmokingstatuswithsarscov2infectionhospitalizationandmortalityfromcovid19alivingrapidevidencereviewwithbayesianmetaanalysesversion7